That MCL-1 antagonism is required for apoptosis mediated by BCL-XL inhibition was hinted at in early papers reporting the activity of ABT-737, where ABT-737 induced apoptosis only in tumours with low MCL-1 levels, and MCL-1 downregulation sensitised resistant cells [75]. The gene discussed is BCL2L1; the disease is neoplasm.